Halozyme Therapeutics (HALO) EPS (Basic) (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly EPS (Basic) of $1.27 for Q1 2026, up 32.51% year-over-year from $0.96 in Q1 2025, and up 207.49% quarter-over-quarter from -$1.18 in Q4 2025.
Halozyme Therapeutics (HALO) EPS (Basic) (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported EPS (Basic) for 17 consecutive years, with $1.27 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) rose 32.51% year-over-year to $1.27; the TTM figure through Mar 2026 stood at $2.95 (down 25.04% YoY), while the FY2025 annual figure was $2.64, down 24.48% from the prior year.
- EPS (Basic) climbed to $1.27 in Q1 2026 per HALO's latest filing, from -$1.18 in the prior quarter.
- Across five years, EPS (Basic) topped out at $1.5 in Q3 2025 and bottomed at -$1.18 in Q4 2025.
- Historically, EPS (Basic) has averaged $0.65 across 5 years, with a median of $0.62 in 2023.
- Annual changes were most pronounced in 2023 — EPS (Basic) jumped 245.06% — and 2025, when it plunged 209.37%.
- Halozyme Therapeutics' EPS (Basic) stood at $0.42 in 2022, then soared by 53.5% to $0.65 in 2023, then surged by 66.91% to $1.08 in 2024, then plunged by 209.37% to -$1.18 in 2025, then jumped by 207.49% to $1.27 in 2026.
- Business Quant data shows HALO's EPS (Basic) at $1.27 in Q1 2026, -$1.18 in Q4 2025, and $1.5 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 7.59 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.06 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.16 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.18 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.23 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.06 |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 1.96 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.96 |
| Mar 31, 2026 | 1.27 |
| Dec 31, 2025 | -1.18 |
| Sep 30, 2025 | 1.50 |
| Jun 30, 2025 | 1.36 |
| Mar 31, 2025 | 0.96 |
| Dec 31, 2024 | 1.08 |
| Sep 30, 2024 | 1.08 |
| Jun 30, 2024 | 0.73 |
| Mar 31, 2024 | 0.61 |
| Dec 31, 2023 | 0.65 |
| Sep 30, 2023 | 0.62 |
| Jun 30, 2023 | 0.57 |
| Mar 31, 2023 | 0.29 |
| Dec 31, 2022 | 0.42 |
| Sep 30, 2022 | 0.45 |
| Jun 30, 2022 | 0.16 |
| Mar 31, 2022 | 0.44 |
| Dec 31, 2021 | 0.47 |
| Sep 30, 2021 | 1.53 |